Express News | Travere Therapeutics Shares up 4.8% After Co Submits US Marketing Application to the FDA for Kidney Disease Treatment

ReutersMar 17 09:37 ET

Express News | Travere Therapeutics Inc: Continues to Expect a Rems Modification Pdufa Target Action Date of August 28

ReutersMar 17 07:06 ET

Express News | Travere Therapeutics Inc: Plans to Submit Amendment to Rems Snda Currently Under Review for Modification of Liver Monitoring

ReutersMar 17 07:05 ET

Express News | Travere Therapeutics Inc: FDA Notified Company That Rems Monitoring for Embryo-Fetal Toxicity Is No Longer Necessary

ReutersMar 17 07:05 ET

Express News | Travere Therapeutics Submits Snda to FDA for Approval of Filspari® (Sparsentan) for the Treatment of Fsgs

ReutersMar 17 07:04 ET

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireMar 12 17:30 ET